

CV2Ag

VITROS Immunodiagnostic Products SARS-CoV-2 Antigen Controls

REF

619 9943

**Rx ONLY** 

#### Intended Use

For in vitro diagnostic and laboratory professional use.

For use in monitoring the performance of the VITROS 3600 Immunodiagnostic System and the VITROS 5600/XT 7600 Integrated Systems for the qualitative detection of the SARS-CoV-2 nucleocapsid antigen.

## Warnings and Precautions

WARNING:	Potentially Infectious Material

Treat as if capable of transmitting infection.

Handle, use, store and dispose of solid and liquid waste from samples and test components, in accordance with procedures defined by appropriate national biohazard safety guideline or regulation (e.g. CLSI document M29).

#### **WARNING:**

Contains 2-methyl-3(2H) isothiazolone (MIT) (CAS 2682-20-4)2

The VITROS SARS-CoV-2 Antigen Controls contain 0.0475% 2-methyl-3(2H) isothiazolone (MIT). H317: May cause an allergic skin reaction. P261: Avoid breathing dust/fume/gas/mist/vapors/spray. P280: Wear protective gloves. P333 + P313: If skin irritation or rash occurs: Get medical advice/attention. P362 + P364: Take off contaminated clothing and wash it before reuse. P501: Dispose of contents/container to an approved waste disposal plant.

Refer to www.orthoclinicaldiagnostics.com for the Safety Data Sheets and for Ortho contact information.

#### **WARNING**



#### Materials Provided

3 sets of VITROS SARS-CoV-2 Antigen Controls 1 and 2 (recombinant SARS-CoV-2 nucleocapsid antigen in buffer with bovine serum albumin and antimicrobial agent, 3 mL)

#### Materials Required but Not Provided

- Pipette, sample containers
- · VITROS Immunodiagnostic Products SARS-COV-2 Antigen Extraction Buffer

Control Storage, Preparation and Handling

### Control Storage, Preparation and Handling

Control	Storage Condition		Stability
Unopened	Frozen	≤-20 °C (≤-4 °F)	expiration date
Opened	Refrigerated	2-8 °C (36-46 °F)	≤10 weeks
Opened	Frozen	≤-20°C (≤-4°F)	≤10 weeks

- The VITROS SARS-CoV-2 Antigen Controls are supplied frozen.
- Opened controls may be stored frozen (with no more than 1 freeze-thaw cycle).
- VITROS SARS-CoV-2 Antigen Controls are suitable for use until the expiration date on the carton when stored and handled as specified. Do not use beyond the expiration date.
- Thoroughly mix controls by inversion and bring to 15–30 °C (59–86 °F) before use.
- Handle controls in stoppered containers to avoid contamination and evaporation. To avoid evaporation, limit the amount of time controls are on the system. Refer to the operating instructions for your system.
- Return to 2–8 °C (36–46 °F) or ≤-20°C (≤-4°F) as soon as possible after use, or load only sufficient volume for a single determination.
- Baseline statistics for controls should be entered onto the system. For further information, refer to the operating instructions for your system.
- The expiration date for the controls must be entered onto the system. For further information, refer to the operating instructions for your system.

#### **Testing Procedure**

For each control:

- Combine 100 μL VITROS SARS-CoV-2 Extraction Buffer and 400 μL of control into a sample container.
- Mix well (e.g. cover sample container with cap/plug and vortex approx. 3-5 seconds).

Load each control onto the system by transferring an aliquot into a sample container, if needed (taking account of the volume required by the test and the minimum fill volume of the container). Process in the same manner as samples, according to the instructions in the appropriate VITROS Immunodiagnostic Products Reagent Pack and Calibrator instructions for use.

Note:

Do not use visibly damaged product.

For further information on quality control procedures refer to the operating instructions for your system. Not all products and systems are available in all countries.

### **Baseline Statistics**

VITROS SARS-CoV-2 Antigen Control 1 should generate Non-reactive results. VITROS SARS-CoV-2 Antigen Control 2 should generate Reactive results.

#### References


- CLSI Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline—Fourth Edition.
  CLSI document M29-A4. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
- Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006.



Glossary of Symbols

# Glossary of Symbols

The following symbols may have been used in the labeling of this product.



# **Revision History**

Date of Revision	Version	Description of Technical Changes*
2022-07-18	3.0	Control Storage, Preparation and Handling:
		<ul> <li>Updated refrigerated stability from "≤5 days" to "≤10 weeks"</li> </ul>
		<ul> <li>Added frozen stability information</li> </ul>
		<ul> <li>Removed statement "DO NOT REFREEZE"</li> </ul>
		<ul> <li>Added statement regarding opened controls frozen stability</li> </ul>
		<ul> <li>Updated "single determination" statement</li> </ul>

<sup>\*</sup> The change bars indicate the position of a technical amendment to the text with respect to the previous version of the document.





**Revision History** 

When this Instructions For Use is replaced, sign and oppolicies, as appropriate.	date below and retain as specified by local regulations or laboratory
policies, as appropriate.	
Signature	Obsolete Date

Conditions of supply: all supplies are made subject to the standard terms and conditions of Ortho Clinical Diagnostics or its distributors. Copies of these are available on request.

Distributed in the US by: Ortho-Clinical Diagnostics, Inc. 100 Indigo Creek Drive Rochester, NY 14626



EC REP

Ortho-Clinical Diagnostics 1500 Boulevard Sébastien Brant B.P. 30335 67411 Illkirch CEDEX, France



Ortho-Clinical Diagnostics Felindre Meadows Pencoed Bridgend CF35 5PZ United Kingdom

VITROS is a registered trademark of Ortho Clinical Diagnostics. © Ortho Clinical Diagnostics, 2020–2022

# Ortho Clinical Diagnostics